- Visibility 131 Views
- Downloads 118 Downloads
- Permissions
- DOI 10.18231/j.ijced.34242.1758871287
-
CrossMark
Association of serum CXCL-10, IL-22 and IL-6 with types of vitiligo - Study conducted at a tertiary care hospital of Tripura
- Author Details:
-
Syamal Kanti Chakraborti
-
Bidhan Goswami *
-
Shauli Sengupta
-
Partha Saha
Bidhan Goswami *
Shauli Sengupta
Background: According to research conducted in India, the prevalence of vitiligo in dermatology outpatients consistently ranges from 0.25 to 4 percent. From previous studies, it has been reported that the serum level of CXCL-10 is increased in organ specific autoimmune diseases, such as type 1 diabetes, Graves’ disease etc. But the role of CXCL10 in the immunopathogenesis of vitiligo has been highlighted in very few studies.
Objectives: To estimate the serum levels of CXCl-10, IL-6 & IL-22 in patients suffering from Vitiligo reporting in Dermatology Outpatient Department and also to find out the association between these serum biomarkers and clinical status of Vitiligo among the study subjects.
Patients and Methods: The study included One hundred forty-two vitiligo patients who were able to comply with the study protocol reported in the Dermatology Outpatient department of a tertiary teaching hospital of Tripura. All recruited patients were subjected to documentation of complete history. Detailed physical examination was performed for type of vitiligo, the distribution and body surface area (BSA) involvement using palm method and rule of nines. 5 ml Blood Samples were taken after getting written consent from the patient or from the legal guardian in case of children for performing tests namely Serum CxCL-10, IL-6, IL-22 etc. Results: Out of 142 vitiligo patients, 66.2% (94) were Female and 33.8% (48) were Male. According to study result maximum Vitiligo patients of Tripura lie within 11-20 years age group (24.65%). The mean serum levels of CXCL10 and IL-22 in the Vitiligo group was statistically higher in patients with Non-segmental type of Vitiligo.
Conclusion: From this study, we can conclude that increased serum levels of CXCL10 is associated with types of Vitiligo where non-segmental type showed maximum level followed by segmental and focal type respectively.
References
- Zhang Y, Cai Y, Shi M, Jiang S, Cui S, Wu Y, et al.. The Prevalence of Vitiligo: A Meta-Analysis. Plos One. 2016;11(9):e0163806.
- Antonelli A, Fallahi P, Ferrari SM, Pupilli C, D’Annunzio G, Lorini R, et al. Serum Th1 (CXCL10) and Th2 (CCL2) chemokine levels in children with newly diagnosed Type 1 diabetes: a longitudinal study. Diabet Med. 2008;25(11):1349–53.
- Ferrari SM, Fallahi P, Mancusi C, Colaci M, Manfredi A, Ferri C, et al. HCV-related autoimmune disorders in HCV chronic infection. La Clinica Terapeutica. 2013;164(4):e305-12.
- Rätsep R, Kingo K, Karelson M, Reimann E, Raud K, Silm H, et al.. Gene expression study ofIL10family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera. Br J Dermatol. 2008;159(6):1275–81.
- Abou Elela M, Hegazy RA, Fawzy MM, Rashed LA, Rasheed H. Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case-controlled study on eighty- four patients. Eur J Dermatol. 2013;23(3):350–5.
- Kumar S, Nayak C, Padhi T, Rao G, Rao A, Sharma V, et al. Epidemiological pattern of psoriasis, vitiligo and atopic dermatitis in India: Hospital-based point prevalence. Indian Dermatol Online J. 2014;5(5):6–8.
- Sehgal VN, Rege VL, Mascarenhas F, Kharangate VN. Clinical pattern of vitiligo amongst Indians. J Dermatol. 1976;3(2):49–53.
- World Health Organization. WHO guidelines on drawing blood: best practices in phlebotomy. World Health Organization; 2010.
- Gopal K, Rama Rao G, Kumar YK, Appa Rao M, Vasudev P, Srikant. Vitiligo: A part of a systemic autoimmune process. Indian J Dermatol Venereol Leprol. 2007;73(3):162–5.
- Shah H, Mehta A, Astik B. Clinical and sociodemographic study of vitiligo. Indian J Dermatol Venereol Leprol. 2008;74(6):701.
- Singh S, Pandey SS. Epidemiological profile of vitiligo in Northern India. J Appl Pharm Sci. 2011;1(10):211–4.
- Al-Mutairi N, Sharma AK, Zaki A, Shiltawi M, Nouridin O. Profile of vitiligo in Farwaniya region in Kuwait. KMJ-Kuwait Med J. 2006;38(2):128–31.
- Nunes DH, Esser LM. Vitiligo epidemiological profile and the association with thyroid disease. Anais Brasileiros de Dermatologia. 2011;86(2):241–8.
- Surekha T, Ishaq M, Latha KP, Rao PH, Jahan P. Do clinical variants of vitiligo involve x-chromosomal gene (s) too?. J Med Sci. 2008;8(8):728–33.
- Liu J, Li M, Yang S, Gui J, Wang H, Du W, et al. Clinical profiles of vitiligo in China: an analysis of 3742 patients. Clin Exp Dermatol. 2005;30(4):327–31.
- Dave S, Thappa DM, DSouza M. Clinical predictors of outcome in vitiligo. Indian J Dermatol Venereol Leprol. 2002;68(6):323–5.
- Alkhateeb A, Fain PR, Thody A, Bennett DC, Spritz RA. Epidemiology of Vitiligo and Associated Autoimmune Diseases in Caucasian Probands and Their Families. Pigment Cell Res. 2003;16(3):208–14.
- Shah H, Mehta A, Astik B. Clinical and sociodemographic study of vitiligo. Indian J Dermatol Venereol Leprol. 2008;74(6):701.
- Rashighi M, Agarwal P, Richmond JM, Harris TH, Dresser K, Su MW, et al. CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo. Sci Transl Med. 2014;6(223):223ra23.
- Wang XX, Wang QQ, Wu JQ, Jiang M, Chen L, Zhang CF, et al. Increased expression of CXCR3 and its ligands in patients with vitiligo and CXCL10 as a potential clinical marker for vitiligo. Br J Dermatol. 2016;174(6):1318–26.
- Groom JR, Richmond J, Murooka TT, Sorensen EW, Sung JH, Bankert K, et al. CXCR3 chemokine receptor-ligand interactions in the lymph node optimize CD4+ T helper 1 cell differentiation. Immunity. 2012;37(6):1091–103.
- Moretti S, Fabbri P, Baroni G, Berti S, Ban D, Berti E, et al. Keratinocyte dysfunction in vitiligo epidermis: cytokine microenvironment and correlation to keratinocyte apoptosis. Histol Histopathol. 2009;24(7):849-57.
- Singh S, Singh U, Pandey SS. Serum concentration of IL-6, IL-2, TNF-α, and IFNγ in Vitiligo patients. Indian J Dermatol. 2012;57(1):12–4.
- Sushama S, Dixit N, Gautam RK, Arora P, Khurana A, Anubhuti A. Cytokine profile (IL‐2, IL‐6, IL‐17, IL‐22, and TNF‐α) in vitiligo— New insight into pathogenesis of disease. J Cosmet Dermatol. 2019;18(1):337–41.
- Abdallah M, El‐Mofty M, Anbar T, Rasheed H, Esmat S, Al‐Tawdy A, et al. CXCL‐10 and Interleukin‐6 are reliable serum markers for vitiligo activity: A multicenter cross‐sectional study. Pigment Cell Melanoma Res. 2018;31(2):330–6.